Syros Pharmaceuticals, Inc. financial data

Symbol
SYRS on Nasdaq
Industry
Pharmaceutical Preparations
Location
35 Cambridge Park Drive, Cambridge, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Former names
LS22, Inc. (to 8/22/2012)
Latest financial report
10-Q - Q2 2024 - Jul 31, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 366 % -43.9%
Return On Equity -853 % -880%
Return On Assets -94.4 % -127%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 26.5M shares +30.3%
Common Stock, Shares, Outstanding 26.8M shares +29.5%
Entity Public Float 58.6M USD +5.06%
Common Stock, Value, Issued 26K USD +30%
Weighted Average Number of Shares Outstanding, Basic 39.3M shares +40.7%
Weighted Average Number of Shares Outstanding, Diluted 39.3M shares +40.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 9.94M USD -33.2%
Research and Development Expense 96.4M USD -14%
General and Administrative Expense 25.4M USD -15.5%
Operating Income (Loss) -120M USD +15.8%
Net Income (Loss) Attributable to Parent -132M USD -38.4%
Earnings Per Share, Basic -4.35 USD/shares -1640%
Earnings Per Share, Diluted -4.35 USD/shares -1640%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 79M USD -31.6%
Marketable Securities, Current 24.8M USD -59.4%
Cash, Cash Equivalents, and Short-term Investments 108M USD
Assets, Current 84.9M USD -44.4%
Property, Plant and Equipment, Net 6.63M USD -35.6%
Operating Lease, Right-of-Use Asset 11.6M USD -8.97%
Other Assets, Noncurrent 1.46M USD -34.5%
Assets 107M USD -41%
Accounts Payable, Current 7.47M USD +11.6%
Employee-related Liabilities, Current 3.82M USD -24.3%
Liabilities, Current 24.5M USD -13.6%
Operating Lease, Liability, Noncurrent 17.2M USD -12.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax 49K USD
Retained Earnings (Accumulated Deficit) -750M USD -21.3%
Stockholders' Equity Attributable to Parent -6.35M USD -109%
Liabilities and Equity 107M USD -41%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -31.1M USD +15.7%
Net Cash Provided by (Used in) Financing Activities -265K USD
Net Cash Provided by (Used in) Investing Activities -24.6M USD +4.3%
Common Stock, Shares Authorized 140M shares +100%
Common Stock, Shares, Issued 26.8M shares +29.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -56M USD +10.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 81.1M USD -31.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.21M USD +14.8%
Deferred Tax Assets, Valuation Allowance 169M USD +31.7%
Deferred Tax Assets, Gross 174M USD +29.8%
Operating Lease, Liability 20.3M USD -9.3%
Payments to Acquire Property, Plant, and Equipment 235K USD +83.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -132M USD -39%
Lessee, Operating Lease, Liability, to be Paid 26.7M USD -13.3%
Property, Plant and Equipment, Gross 14.9M USD -37.5%
Operating Lease, Liability, Current 2.5M USD +15.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.41M USD +2.92%
Lessee, Operating Lease, Liability, to be Paid, Year One 4.29M USD +2.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 6.38M USD -23.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 4.54M USD +2.92%
Deferred Tax Assets, Operating Loss Carryforwards 95.3M USD +16.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 4.54M USD +2.92%
Operating Lease, Payments 1.04M USD +2.98%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 334K USD -47.6%
Deferred Tax Assets, Net of Valuation Allowance 4.72M USD -14.2%
Share-based Payment Arrangement, Expense 8.88M USD -21.5%
Interest Expense 5.32M USD +13.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%